Compare American Financial Group Inc (AFG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? American Financial Group Inc trades at $144.65 (market cap $11.97B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: American Financial Group Inc pays a 2.44% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, American Financial Group Inc nearer its low. Which is the better fit depends on your goals.
| AFG | XBI | |
|---|---|---|
Market Cap | $11.97B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $148.71 | $164.28 |
52-Week Low | $124.18 | $86.92 |
Enterprise Value | $12.35B | — |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $144.77, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $2.82 per share, beating estimates, driven by property and casualty underwriting and investment income. Revenue for 2025 was $8.12 billion with a net income margin of 10.37%, while 2026 projections show improved profitability. A dividend of $0.88 per share is scheduled for payment in July 2026.
AFG presents a positive outlook with analyst consensus price target of $160.67, implying potential upside. Strengths include consistent earnings beats and robust ROE of 20.41%. Risks involve earnings volatility, as seen in Q1 2026 miss, and competitive insurance market pressures. Institutional activity is mixed, with some reducing holdings while others increase positions. The stock is a hold for growth-oriented investors monitoring earnings consistency.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
